Presentation is loading. Please wait.

Presentation is loading. Please wait.

BV6 increases tumor burden in bone.

Published by Modified over 6 years ago

Similar presentations

Presentation on theme: "BV6 increases tumor burden in bone."— Presentation transcript:

1 BV6 increases tumor burden in bone.
BV6 increases tumor burden in bone. A, cultured MDA-MB-231-Fluc cells were incubated with BV6 (5 μmol/L) for 2 days, and then viability was measured by MTT assay. B, scheme of tumor inoculation. Female nude mice (homozygous CrTac:NCr-Foxn1nu) were intraperitoneally injected with BV6 (10 mg/kg) or vehicle (Veh), with 3 weekly doses before and 5 biweekly doses after tumor inoculation. Six-week-old mice were intraventricularly and subcutaneously injected with 1 × 105 and 1 × 104 MDA-MB-231-Fluc, respectively, and then imaged on days 11, 14, and 18. C and D, tumor burden of BV6- and vehicle-treated mice in the soft tissue and skeleton (legs and jaw) are plotted. Vehicle, n = 7; BV6, n = 8. E, cultured 4T1-Fluc cells were incubated with BV6 (5 μmol/L) for 2 days, and then viability was measured by MTT assay. F, scheme of tumor inoculation. Male BALB/c mice were treated with BV6 or vehicle once per week for 4 weeks, and 1 × 104 4T1-Fluc cells were inoculated directly into left tibias when mice were 6 weeks old. Right tibias were injected with PBS. Bioluminescence from tibias was measured on days 4, 7, and 10 after tumor inoculation. G, tumor burden of BV6- and vehicle-treated mice in the tibias is plotted. Vehicle, n = 7; BV6, n = 5. H, representative images of G on day 10 are shown. I, mice from G were sacrificed on day 10 and the tibias were subjected to histomorphometric analysis. Tumor occupancy was measured by the ratio of tumor area over total area of the bone marrow cavity. T, tumor; B, bone marrow. J, representative images of I are shown. K, tumor and PBS-injected tibias were scanned by μCT, and BV/TV was calculated. L, representative photos of K are shown. M, 6-week-old BALB/c mice were subcutaneously injected with 1 × 105 4T1-Fluc, and mice were imaged on day 10. Tumor burden is plotted. n = 5/group. Scale bar, 500 μm. Data represent the mean ± SD; n.s., not significant; *, P < 0.05; **, P < 0.01; ***, P < Chang Yang et al. Cancer Discovery 2013;3: ©2013 by American Association for Cancer Research

Download ppt "BV6 increases tumor burden in bone."

Similar presentations

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.
Camacho et al, Fig. S1 a c e b d f

Camacho et al, Fig. S1 a c e b d f
Drug concentration (μM)

Drug concentration (μM)
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.

Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.
18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.
Binding of 53BP1 on uncapped telomeres.

Binding of 53BP1 on uncapped telomeres.
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.
Validation of St6GalNAc2 as a metastasis suppressor gene.

Validation of St6GalNAc2 as a metastasis suppressor gene.
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.
A role for galectin-3 in promoting lung colonization in ST6GalNAc2-silenced cells. A role for galectin-3 in promoting lung colonization in ST6GalNAc2-silenced.

A role for galectin-3 in promoting lung colonization in ST6GalNAc2-silenced cells. A role for galectin-3 in promoting lung colonization in ST6GalNAc2-silenced.
Fig. 5 Local gel scaffold for T cell memory response.

Fig. 5 Local gel scaffold for T cell memory response.
Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.
Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines  Wei Zhang, PhD, Michael.

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines  Wei Zhang, PhD, Michael.
Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.

Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.
Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.
Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Similar presentations

Ads by Google